Daniel Cendan is a Partner in Freshfields’ global investigations, corporate crime and white-collar defense, and international disputes practice groups. Daniel represents clients across a broad range of industries in high-stakes government investigations, corporate internal investigations, strategic risk and crisis management, and other compliance, regulatory and administrative matters. He also regularly advises global companies on their compliance programs and addressing compliance risks, including challenges confronting compliance professionals and entities who receive funding from multilateral development banks.
Daniel works closely with firm lawyers around the world, coordinating global investigations and multi-jurisdictional compliance risk assessments, developing compliance and training programs, and conducting due diligence and advising private equity and corporate clients on risk-assessment and mitigation strategies in connection with cross-border deals and emerging-market M&A.
Daniel handles matters for US and international clients facing criminal and civil investigations at both the federal and state levels, and assists clients with their own internal inquiries and compliance program reviews. He has particular experience counseling clients in multi-jurisdictional investigations and matters involving compliance with the US Foreign Corrupt Practices Act (FCPA) and other anti-corruption laws, international compliance risks, sanctions and trade compliance and unfair trade practices, as well as investigating claims made under the False Claims Act (FCA) and federal anti-kickback law. Daniel has also defended companies under investigation for alleged prohibited practices before the sanctions systems of the multilateral development banks (MDBs), and has also advised on negotiated resolutions.
Daniel has been recognized in 2025 Lawdragon 500 Leading Litigators in America (selected for white collar, investigations, and enforcement), and Latin Lawyer 250 for Anti-Corruption Investigations and Compliance, is a GIR Insight Contributor, and has been appointed to Law360’s Editorial Advisory Board for Compliance.
- Represented global engineering and consulting company in MDB sanctions proceedings involving allegations of fraudulent and corrupt practices, and advised on negotiated resolution and post-resolution compliance commitments.
- Counseled leading multinational company in investigations conducted by the DOJ and SEC relating to procurement processes of minority-owned joint ventures in certain Latin American countries, and advised on related anti-bribery and corruption diligence and internal reviews.
- Counseled multinational manufacturing company in connection with FCPA, sanctions, and compliance-related risks associated with operations in former Soviet republics in Eastern Europe.
- Served as FCPA counsel and conducted global anti-bribery and corruption reviews and compliance program assessments for a multinational company in the industrials sector.
- Defended global pharmaceutical company in connection with a FCPA investigation by the DOJ and SEC, resulting in a declination of criminal prosecution by the DOJ and a favorable settlement with the SEC.
- Defended respondent company and its CEO in MDB sanctions proceedings involving charges of corrupt and fraudulent practices relating to certain MDB-financed projects in the Caribbean.
- Counseled medical device companies in investigations conducted by DOJ and state Attorneys General regarding relationships with healthcare professionals, disclosure of clinical trial data, and promotion and safety of various products.
- Advised multinational energy corporation on developing compliance and training programs tailored to relevant global regulatory regimes.
- Counseled multinational technology company on compliance and regulatory risks in certain countries in Latin America.
- Represented multinational pharmaceutical company in Justice Department investigations, congressional hearings, and resolutions with state Attorneys General involving allegations of off-label promotion of prescription medications, improper relationships with healthcare officials, and safety of medications.
- Counseled global real estate investment company in an investigation relating to allegations of bribery and corruption in one of the company’s subsidiaries in Asia.
- Conducted pre-acquisition due diligence for a global pharmaceutical company and assessed corruption risks associated with a multibillion-dollar asset swap, including advising on key transaction terms, compliance representations and warranties and related indemnities.
